GBS

Adjuvant Capital announced last week a $300 million Global Health Technology Fund focused on accelerating the development of medical innovations for “historically overlooked public health challenges.”

The New York-based social impact investor noted in its press release that it has already backed 14 companies, requiring each to make products broadly accessible to people in low- and middle-income countries. Adjuvant’s “young portfolio” includes investments in companies addressing…

Denmark’s MinervaX announced Tuesday that it has raised $57 million to advance its protein-only Group B Streptococcus (GBS) vaccine candidate through Phase 2 and to prepare for Phase 3 trials.

According to the press release, the Series B round “included Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden”—along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures and LF Investment.

Rival Pfizer released positive Phase 1/2…

The Lancet published Phase 1/2 results last week that gave a boost to Pfizer’s novel Group B Streptococcus (GBS) conjugate vaccine.

The Pfizer-led research team said the hexavalent shot was well tolerated and generated robust immune responses persisting six months after vaccination in healthy nonpregnant adults aged 18-49.

Other companies with GBS candidates include Denmark’s MinervaX, India’s Hilleman Labs and GSK.

Mentions:

Pfizer announced epidemiological findings this week showing that the burden of Group B Streptococcus (GBS) infections in the United States is “greater than previously recognized.”

The study, published in The Journal of Infectious Diseases, estimates that 188,570 GBS-related hospitalizations occur each year among U.S. adults 18 or older, with significantly higher rates in adults over 65, African Americans, and people with chronic conditions.

According to the company’s press…

India’s Hilleman Laboratories last week announced plans to develop an “effective and affordable" Group B Streptococcus vaccine, paying “close attention” to strains prevalent in India and Southeast Asia, according to a company press release. If successful, the company expects to partner with a vaccine manufacturer for production, a model it followed last year when licensing its oral cholera vaccine candidate to Hyderabad-based Bharat Biotech International Limited.

The press release said…

Pfizer announced this week it has begun Phase 1 clinical trials of its Group B Streptococcus (GBS) vaccine candidate, PF-06760805. The trial is being conducted in the United States and will evaluate healthy adults aged 18 to 45 with no history of a GBS infection.

Pfizer’s press release said the company intends to make a successfully developed vaccine available globally as quickly as possible and that it is pursuing a clinical development strategy in high, middle and low-income…

Mentions:

Media group Bloomberg launched a month-long focus this week on the pharmaceutical industry with reporting on maternal immunization, antimicrobial resistance, Zika, drug pricing, and an interview with Gates Foundation co-chair, Bill Gates.

Bloomberg gave positive coverage to GSK, Pfizer and Novavax for working on group B strep and respiratory syncytial virus vaccines for maternal immunization, and to the sector as a whole for intending to increase spend on antimicrobial resistance R…